e-learning
resources
Virtual 2021
05.09.2021
Asthma clinical trials and real-life studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
M. Przybyszowski (Kraków, Poland), I. Gross-Sondej (Kraków, Poland), J. Zarychta (Zakopane, Poland), S. Bazan-Socha (Kraków, Poland), G. Bochenek (Kraków, Poland), J. Soja (Kraków, Poland), K. Sladek (Kraków, Poland)
Source:
Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session:
Asthma clinical trials and real-life studies
Session type:
E-poster
Number:
894
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Przybyszowski (Kraków, Poland), I. Gross-Sondej (Kraków, Poland), J. Zarychta (Zakopane, Poland), S. Bazan-Socha (Kraków, Poland), G. Bochenek (Kraków, Poland), J. Soja (Kraków, Poland), K. Sladek (Kraków, Poland). Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.. 894
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Year: 2019
Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients
Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Year: 2020
Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept